Abstract
Background:
Multipotent mesenchymal stromal cells (MSCs) are used for prophylaxis of acute graft-versus-host disease (aGvHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Not all samples of MSC are efficient for aGvHD prevention. The suitability of MSCs for aGvHD prophylaxis was studied.
Methods:
MSCs were derived from the bone marrow (BM) of HCT donor and cultivated for no more than three passages. The characteristics of donor BM samples including colony-forming unit fibroblast (CFU-F) concentration, growth parameters of MSCs, and the relative expression levels (REL) of different genes were analyzed. MSCs were injected intravenously precisely at the moment of blood cell reconstitution.
Results:
MSCs infusion induced a significant threefold decrease in aGvHD development and improved overall survival compared with the standard prophylaxis group. In ineffective MSC samples (9.4%), a significant decrease in total cell production and the REL of CSF1, FGFR1, and PDGFRB was observed. In all studied BM samples, the cumulative MSC production and CFU-F concentrations decreased with age. The expression levels of FGFR2, PPARG, and VEGF differed by age.
Conclusions:
A universal single indicator for the prediction of MSC eligibility for aGvHD prophylaxis was not identified. A multiparameter mathematical model for selecting MSC samples effective for the prevention of aGvHD was proposed.
Keywords:
acute graft-versus-host disease prophylaxis; colony-forming unit fibroblast; gene expression; mesenchymal stromal cell.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Female
-
Gene Expression
-
Graft vs Host Disease / diagnosis
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / mortality
-
Graft vs Host Disease / prevention & control*
-
Humans
-
Leukemia, Myeloid, Acute / immunology
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / pathology
-
Leukemia, Myeloid, Acute / therapy
-
Male
-
Mesenchymal Stem Cell Transplantation*
-
Mesenchymal Stem Cells / cytology
-
Mesenchymal Stem Cells / immunology*
-
Middle Aged
-
Myeloablative Agonists / therapeutic use*
-
Myelodysplastic Syndromes / immunology
-
Myelodysplastic Syndromes / mortality
-
Myelodysplastic Syndromes / pathology
-
Myelodysplastic Syndromes / therapy
-
PPAR gamma / genetics
-
PPAR gamma / immunology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Receptor, Fibroblast Growth Factor, Type 1 / genetics
-
Receptor, Fibroblast Growth Factor, Type 1 / immunology
-
Receptor, Fibroblast Growth Factor, Type 2 / genetics
-
Receptor, Fibroblast Growth Factor, Type 2 / immunology
-
Receptor, Macrophage Colony-Stimulating Factor / genetics
-
Receptor, Macrophage Colony-Stimulating Factor / immunology
-
Receptor, Platelet-Derived Growth Factor beta / genetics
-
Receptor, Platelet-Derived Growth Factor beta / immunology
-
Survival Analysis
-
Transplantation Conditioning / methods*
-
Transplantation, Homologous
Substances
-
Myeloablative Agonists
-
PPAR gamma
-
FGFR1 protein, human
-
FGFR2 protein, human
-
PDGFRB protein, human
-
Receptor, Fibroblast Growth Factor, Type 1
-
Receptor, Fibroblast Growth Factor, Type 2
-
Receptor, Macrophage Colony-Stimulating Factor
-
Receptor, Platelet-Derived Growth Factor beta